Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Obstet Gynaecol ; 43(1): 2160928, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36576124

RESUMO

It is not standardised what is the endometrial thickness that discriminates between normal and potentially malignant. The objective of this study was to determine the endometrial thickness cut-off point from which the risk of endometrial cancer (EC) increases in asymptomatic postmenopausal women; and to evaluate the risk factors linked to malignant endometrial pathology as well as other associated ultrasound findings.This was a retrospective observational study that included hysteroscopies performed at the Hospital Materno-Infantil on 267 asymptomatic menopausal women with an increase in endometrial thickness (AET) >5 mm, from 2015 to 2019. The results shows that the prevalence of malignant pathology in asymptomatic postmenopausal women with a casual finding of endometrial thickening was 3.7%. This percentage was 16.3% when the cut-off point of AET was established at 10 mm. There was a significant association for the diagnosis of malignant pathology with this cut-off point.There is a significant association between the 10 mm endometrial thickness cut-off point from which the risk of EC increases in asymptomatic postmenopausal women.Impact statementWhat is already known on this subject? Several studies have established the cut-off point for asymptomatic endometrial thickening (AET) for atypical endometrial hyperplasia and endometrial cancer at 10 mm. Although no cut-off point has optimal accuracy for the diagnosis of malignant endometrial pathology, it has been found that with a cut-off value of AET >10 mm no cases are missed. Likewise, a cut-off point of AET > 11 mm may provide a balance between cancer detection and histopathological workup extension.What do the results of this study add? A significant association was found at the cut-off point of AET > 10 mm, which suggests that screening postmenopausal women at this thickness is acceptable and unlikely to miss cases of endometrial hyperplasia and endometrial cancer.What are the implications of these findings for clinical practice and/or further research? After analysing our results we can conclude, like other published studies, that by establishing a cut-off point of 10 mm we obtain a good discrimination between benign and malignant pathology, which would allow us to diagnose 100% of malignant pathology. Above this cut-off point, the risk of endometrial cancer increases, and it would therefore be advisable to extend the study. A multicentre study is needed to confirm the cut-off point at which the risk of endometrial cancer increases in postmenopausal women with asymptomatic endometrial thickening.


Assuntos
Hiperplasia Endometrial , Neoplasias do Endométrio , Endométrio , Histeroscopia , Feminino , Humanos , Gravidez , Hiperplasia Endometrial/diagnóstico , Neoplasias do Endométrio/diagnóstico por imagem , Neoplasias do Endométrio/epidemiologia , Endométrio/diagnóstico por imagem , Endométrio/patologia , Histeroscopia/métodos , Pós-Menopausa , Ultrassonografia , Hemorragia Uterina/patologia , Estudos Retrospectivos
2.
J Obstet Gynaecol ; 42(8): 3435-3440, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37017372

RESUMO

Twenty-five percent of cases of endometrial cancer appear in women with unfulfilled reproductive desires. An adequate selection of patients and a close hysteroscopic follow-up to monitor the endometrial response to the levonorgestrel-releasing intrauterine system (LNG-IUS) may be a valid and safe option for these patients. This is a case series and review of the literature study. We included eight patients diagnosed of complex endometrial hyperplasia with atypia (CEHA) or stage 1AG1 well-differentiated endometrial cancer without myometrial invasion who desired to get pregnant and opted for a conservative treatment. Follow-up was performed with hysteroscopy and directed biopsy at 3, 6 and 12 months. Of the 854 cases of complex endometrial hyperplasia with atypia (CEHA)/endometrial cancer were diagnosed, 2.3% were candidates for conservative management. We obtained a favourable regression of 71.2% at 6 months and 57% at one year with hormonal treatment. Conservative treatment in complex endometrial hyperplasia with atypia (CEHA)/low-grade endometrial cancer in reproductive age patients with a strong desire for pregnancy is feasible.


Assuntos
Anticoncepcionais Femininos , Hiperplasia Endometrial , Neoplasias do Endométrio , Dispositivos Intrauterinos Medicados , Gravidez , Humanos , Feminino , Hiperplasia Endometrial/tratamento farmacológico , Hiperplasia Endometrial/patologia , Levanogestrel/uso terapêutico , Tratamento Conservador , Histeroscopia , Neoplasias do Endométrio/terapia , Neoplasias do Endométrio/patologia
3.
Prog. obstet. ginecol. (Ed. impr.) ; 49(10): 593-596, oct. 2006. tab
Artigo em Es | IBECS (Espanha) | ID: ibc-048500

RESUMO

La trombosis venosa cerebral es una enfermedad poco frecuente durante el embarazo. En un 25-40% de los casos es de causa desconocida. Los factores predisponentes más frecuentes relacionados con esta enfermedad son: infección, embarazo, puerperio, deshidratación, anticonceptivos orales, coagulopatías, tumores y traumatismos. Un adecuado diagnóstico y un tratamiento precoz pueden proporcionar un buen pronóstico. Presentamos un caso de trombosis de seno sagital superior y seno transverso izquierdo cerebral en una paciente de 30 años de edad, gestante de 12 semanas


Cerebral venous thrombosis is an uncommon disease during pregnancy. In 25-40% of cases, the etiology is unknown. Risk factors are infectious diseases, pregnancy, puerperium, dehydration, oral contraception use, hypercoagulative states, tumors, and traumatism. With correct diagnosis and early treatment, outcome is usually favorable. We present a case of venous sinus thrombosis in a 30-year-old woman at 12 weeks' gestation


Assuntos
Feminino , Gravidez , Adulto , Humanos , Veias Cerebrais/fisiopatologia , Trombose Intracraniana/terapia , Complicações Cardiovasculares na Gravidez/terapia , Fatores de Risco , Espectroscopia de Ressonância Magnética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA